RAB22A As a Predictor of Exosome Secretion in the Progression and Relapse of Multiple Myeloma

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2024 Mar 2

PMID 38431306

Authors

Bingjie Fan

Li Wang

Jishi Wang

Affiliations

Soon will be listed here.

Abstract

Background: Multiple myeloma (MM) is an incurable malignant plasma cell disease. We explored the role of RAB22A in exosome secretion, epithelial-mesenchymal transition (EMT) and immune regulation.

Methods: We obtained MM samples from Gene Expression Omnibus (GEO) data sets. We downloaded the "IOBR" package, and used the "PCA" and "ssGSEA" algorithms to calculate the EMT scores and exosome scores. The "CIBERSORT" package was used to analyze the infiltration of immune cells. We extracted the exosomes of mesenchymal stem cell (MSC) to verify the biological function of RAB22A.

Results: The expression level of RAB22A in smoldering multiple myeloma (SMM) and MM patients was significantly higher than that in normal people and monoclonal gammopathy of undetermined significance (MGUS) patients, and the expression level of RAB22A in relapse MM patients was significantly higher than that in newly diagnosed patients. The EMT scores and exosome scores of high RAB22A group were significantly higher than those of low RAB22A group, and the exosome scores of MSC in recurrent patients were significantly higher than those of newly diagnosed patients. In addition, the infiltration levels of monocyte, NK cells resting, eosinophils, T cells regulatory and T cells CD4 memory activated were positively correlated with RAB22A. After down-regulating the expression of RAB22A in MM-MSC, the secretion of exosomes decreased. Compared with the exosomes of MSC in si-RAB22A group, the exosomes in control group significantly promoted the proliferation of MM.

Conclusions: RAB22A is a potential therapeutic target to improve the prognosis of MM, which is closely related to exosome secretion, EMT and immune cell infiltration.

Citing Articles

Therapeutically Harnessing Tumor Cell-Derived Extracellular Vesicles for Multiple Myeloma: Recent Advances and Future Perspectives.

Xiao S, Chen L, Chen Z, Li Q Pharmaceutics. 2024; 16(11).

PMID: 39598562 PMC: 11597712. DOI: 10.3390/pharmaceutics16111439.

References

Low R, Fung K, Gao H, Preaudet A, Dagley L, Yousef J . S100 family proteins are linked to organoid morphology and EMT in pancreatic cancer. Cell Death Differ. 2023; 30(5):1155-1165. PMC: 10154348. DOI: 10.1038/s41418-023-01126-z. View

Rajkumar S . Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022; 97(8):1086-1107. PMC: 9387011. DOI: 10.1002/ajh.26590. View

Zhao J, Xu Q, Ma S, Li C, Zhang H, Zhao L . Recent advance of small-molecule drugs for clinical treatment of multiple myeloma. Eur J Med Chem. 2023; 257:115492. DOI: 10.1016/j.ejmech.2023.115492. View

Hemminki K, Forsti A, Hansson M . Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016. Sci Rep. 2021; 11(1):17272. PMC: 8390646. DOI: 10.1038/s41598-021-96804-8. View

Borella G, Da Ros A, Borile G, Porcu E, Tregnago C, Benetton M . Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia. Blood. 2021; 138(7):557-570. DOI: 10.1182/blood.2020009845. View

Liao D, Zhong L, Yin J, Zeng C, Wang X, Huang X . Chromosomal translocation-derived aberrant Rab22a drives metastasis of osteosarcoma. Nat Cell Biol. 2020; 22(7):868-881. DOI: 10.1038/s41556-020-0522-z. View

Yin Y, Zhang B, Wang W, Fei B, Quan C, Zhang J . miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A. Clin Cancer Res. 2014; 20(23):6187-99. DOI: 10.1158/1078-0432.CCR-14-1030. View

Caraccio C, Krishna S, Phillips D, Schurch C . Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions. Front Immunol. 2020; 11:501. PMC: 7193016. DOI: 10.3389/fimmu.2020.00501. View

Gu J, Wang M, Wang X, Li J, Liu H, Lin Z . Exosomal miR-483-5p in Bone Marrow Mesenchymal Stem Cells Promotes Malignant Progression of Multiple Myeloma by Targeting TIMP2. Front Cell Dev Biol. 2022; 10:862524. PMC: 8921260. DOI: 10.3389/fcell.2022.862524. View

10.

Xiao Q, Lin C, Peng M, Ren J, Jing Y, Lei L . Circulating plasma exosomal long non-coding RNAs LINC00265, LINC00467, UCA1, and SNHG1 as biomarkers for diagnosis and treatment monitoring of acute myeloid leukemia. Front Oncol. 2022; 12:1033143. PMC: 9585262. DOI: 10.3389/fonc.2022.1033143. View

11.

Gao Y, Zheng X, Chang B, Lin Y, Huang X, Wang W . Intercellular transfer of activated STING triggered by RAB22A-mediated non-canonical autophagy promotes antitumor immunity. Cell Res. 2022; 32(12):1086-1104. PMC: 9715632. DOI: 10.1038/s41422-022-00731-w. View

12.

Nishikawa H, Koyama S . Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer. 2021; 9(7). PMC: 8327843. DOI: 10.1136/jitc-2021-002591. View

13.

Zhu A, Abbas A, Ruiz de Galarreta M, Guan Y, Lu S, Koeppen H . Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022; 28(8):1599-1611. DOI: 10.1038/s41591-022-01868-2. View

14.

Xia C, Wang T, Cheng H, Dong Y, Weng Q, Sun G . Mesenchymal stem cells suppress leukemia via macrophage-mediated functional restoration of bone marrow microenvironment. Leukemia. 2020; 34(9):2375-2383. PMC: 7987218. DOI: 10.1038/s41375-020-0775-3. View

15.

Gentile M, Vigna E, Palmieri S, Galli M, Derudas D, Mina R . Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials. Haematologica. 2023; 109(1):245-255. PMC: 10772491. DOI: 10.3324/haematol.2023.283251. View

16.

Dahlhoff J, Manz H, Steinfatt T, Delgado-Tascon J, Seebacher E, Schneider T . Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression. Leukemia. 2021; 36(3):790-800. PMC: 8885410. DOI: 10.1038/s41375-021-01422-y. View

17.

Xu S, de Veirman K, De Becker A, Vanderkerken K, Van Riet I . Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?. Leukemia. 2018; 32(7):1500-1514. PMC: 6035148. DOI: 10.1038/s41375-018-0061-9. View

18.

Landgren O, Kyle R, Pfeiffer R, Katzmann J, Caporaso N, Hayes R . Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009; 113(22):5412-7. PMC: 2689042. DOI: 10.1182/blood-2008-12-194241. View

19.

Wu J, Zeng D, Zhi S, Ye Z, Qiu W, Huang N . Single-cell analysis of a tumor-derived exosome signature correlates with prognosis and immunotherapy response. J Transl Med. 2021; 19(1):381. PMC: 8424990. DOI: 10.1186/s12967-021-03053-4. View

20.

Pyzer A, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M . MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017; 129(13):1791-1801. PMC: 5813734. DOI: 10.1182/blood-2016-07-730614. View